DE122009000058I1 - Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten - Google Patents

Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten

Info

Publication number
DE122009000058I1
DE122009000058I1 DE122009000058C DE122009000058C DE122009000058I1 DE 122009000058 I1 DE122009000058 I1 DE 122009000058I1 DE 122009000058 C DE122009000058 C DE 122009000058C DE 122009000058 C DE122009000058 C DE 122009000058C DE 122009000058 I1 DE122009000058 I1 DE 122009000058I1
Authority
DE
Germany
Prior art keywords
new
soluble carbohydrate
moiety
immunogenic constructs
preparing immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE122009000058C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Publication of DE122009000058I1 publication Critical patent/DE122009000058I1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE122009000058C 1993-09-22 1994-09-21 Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten Pending DE122009000058I1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12449193A 1993-09-22 1993-09-22
PCT/US1994/010658 WO1995008348A1 (en) 1993-09-22 1994-09-21 Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs

Publications (1)

Publication Number Publication Date
DE122009000058I1 true DE122009000058I1 (de) 2009-12-31

Family

ID=22415196

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69433341T Expired - Lifetime DE69433341T2 (de) 1993-09-22 1994-09-21 Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
DE122009000058C Pending DE122009000058I1 (de) 1993-09-22 1994-09-21 Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69433341T Expired - Lifetime DE69433341T2 (de) 1993-09-22 1994-09-21 Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten

Country Status (13)

Country Link
US (2) US5651971A (de)
EP (1) EP0720485B1 (de)
JP (1) JP3828145B2 (de)
KR (1) KR100376361B1 (de)
AT (1) ATE254475T1 (de)
AU (1) AU678613B2 (de)
CA (1) CA2171942C (de)
DE (2) DE69433341T2 (de)
ES (1) ES2210262T3 (de)
FR (1) FR12C0059I2 (de)
NL (2) NL300412I1 (de)
NZ (1) NZ274376A (de)
WO (1) WO1995008348A1 (de)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5849301A (en) * 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
NZ274376A (en) * 1993-09-22 1997-11-24 Jackson H M Found Military Med Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs
NZ304715A (en) * 1995-03-22 1999-07-29 Jackson H M Found Military Med Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
AU716806B2 (en) * 1995-04-17 2000-03-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
AU2429397A (en) * 1996-03-29 1997-10-22 David S. Terman Polymerized staphylococcal protein a for treatment of diseases
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
EP0912195B1 (de) 1996-06-25 2009-01-21 Pepscan Systems B.V. Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
ES2230687T3 (es) * 1997-04-24 2005-05-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Copulacion de proteinas nomodificadas con polisacaridos derivados de haloacilo o de dihaloacilo para la preparacion de vacunas que incluyen proteinas-polisacaridos.
US5929049A (en) 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
US6284250B1 (en) * 1998-02-05 2001-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
AU3005499A (en) * 1998-03-16 1999-10-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to type-2 cell-independent antigens conjugated to lipid or lipid-containing moieties
WO1999052548A2 (en) * 1998-04-10 1999-10-21 Andrew Lees Conjugate vaccines for the prevention of dental caries
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP1086231A2 (de) 1998-06-12 2001-03-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine Verstärkung der b-zellaktivierung und immunoglobulinsekretion durch costimulierung von rezeptoren für antigen und ebv gp350/220
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
CA2714833A1 (en) * 1998-07-20 2000-02-03 Edward Konadu (Deceased) Vaccines against escherichia coli o157 infection
US6585973B1 (en) 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
CN100339130C (zh) 1999-03-19 2007-09-26 史密丝克莱恩比彻姆生物有限公司 疫苗
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
UA76952C2 (uk) * 2000-06-29 2006-10-16 Глаксосмітклайн Байолоджікалз С.А. Полівалентна імуногенна композиція, спосіб її виготовлення, застосування у виробництві лікарського засобу для лікування або попередження захворювань, викликаних інфекцією haemophilus influenzae типу в та спосіб імунізації людини-хазяїна від захворювання, викликаного haemophilus influenzae типу в
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2003015815A1 (en) * 2001-08-21 2003-02-27 The Brigham And Women's Hospital, Inc. Improved conjugate vaccines
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
MXPA05003863A (es) 2002-10-11 2005-09-08 Chiron Srl Vacunas polipeptidicas para amplia proteccion contra lineas hipervirulentas de meningococos.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CN102302776B (zh) 2003-01-30 2014-06-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
EP1601381A2 (de) 2003-03-07 2005-12-07 Wyeth Holdings Corporation Polysaccharid staphylokokken-oberflächen-adhesin-trägerprotein-konjugate zur immunisierung gegen nosokomialinfektionen
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
PT1961426E (pt) 2003-10-02 2011-06-28 Novartis Vaccines & Diagnostic Vacinas combinadas contra a meningite
EP1713508A2 (de) * 2004-01-29 2006-10-25 Biosynexus Incorporated Verwendung von aminoox-funktionalen gruppen bei der herstellung von vakzine-konjugaten
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
BRPI0510315A (pt) 2004-04-30 2007-10-16 Chiron Srl integração de vacinação com conjugado meningocócico
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
US7456000B2 (en) * 2004-08-26 2008-11-25 Siemens Healthcare Diagnostics Inc. Deactivation of linking moieties in antibody-enzyme conjugates
AU2005287532B2 (en) 2004-09-22 2011-09-01 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
EP2425856A1 (de) 2005-04-08 2012-03-07 Wyeth LLC Multivalente Pneumokokken-Polysaccharidproteinkonjugatzusammensetzung
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
MY150719A (en) 2005-12-22 2014-02-28 Glaxosmithkline Biolog Sa Pneumococcal polysaccharide conjugate vaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
KR101411425B1 (ko) * 2006-03-17 2014-06-24 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
AU2007229449A1 (en) 2006-03-22 2007-10-04 Novartis Ag Regimens for immunisation with meningococcal conjugates
KR101541383B1 (ko) 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
PL2097102T3 (pl) 2006-09-07 2012-10-31 Glaxosmithkline Biologicals Sa Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
AU2008248640A1 (en) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
US9610340B2 (en) 2007-06-26 2017-04-04 Glaxosmithkline Biologicals, S.A. Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
EP3058954B1 (de) 2007-08-27 2017-03-01 Longhorn Vaccines and Diagnostics, LLC Immunogene zusammensetzungen und verfahren
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
US9567379B2 (en) 2009-04-03 2017-02-14 The University Of Chicago Compositions and methods related to protein A (SpA) variants
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
NZ597154A (en) 2009-06-22 2013-10-25 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
WO2011041003A2 (en) 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
WO2011017101A2 (en) 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
NZ622048A (en) 2009-08-27 2015-10-30 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
WO2011036560A2 (en) 2009-09-23 2011-03-31 Novartis Ag Glycoconjugate compositions and methods for treatment of hiv
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
WO2011051893A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
CA2836140C (en) 2009-12-17 2016-06-21 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
ES2743156T3 (es) 2010-04-23 2020-02-18 Serum Institute Of India Pvt Ltd Método simple para eliminación simultánea de múltiples impurezas a partir de sobrenadantes de cultivo a niveles ultrabajos
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
WO2012034067A1 (en) 2010-09-09 2012-03-15 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
GB201106225D0 (en) 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
MX354924B (es) 2011-11-07 2018-03-22 Novartis Ag Molecula portadora que comprende un antigeno spr0096 y un spr2021.
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US9968668B2 (en) 2012-04-26 2018-05-15 The University Of Chicago Staphylococcal coagulase antigens and methods of their use
JP6440619B2 (ja) 2012-10-12 2018-12-19 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 混合ワクチン用の架橋されていない無細胞百日咳抗原
US10287330B2 (en) 2012-12-27 2019-05-14 Glaxosmithkline Biologicals S.A. Methods and compositions relating to CRM197
PE20151720A1 (es) 2013-03-08 2015-12-10 Crucell Holland Bv Vacuna acelular contra pertussis
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
WO2015052684A2 (en) * 2013-10-11 2015-04-16 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Polysaccharide-protein conjugates with enhanced immunogenicity and rapid high yielding process thereof
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
SI3583947T1 (sl) 2014-01-21 2024-01-31 Pfizer Inc. Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
US9492559B2 (en) 2014-01-21 2016-11-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2015210674B2 (en) 2014-01-31 2017-08-24 Fina Biosolutions, Llc Expression and purification of CRM197 and related proteins
US10392424B2 (en) 2014-02-28 2019-08-27 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
EP2921856B1 (de) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited Quantitativer test für 4-pyrrolidinopyridin (4-ppy) in konjugatimpfstoffen aus polysaccharid-protein
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
WO2016091904A1 (en) 2014-12-10 2016-06-16 Glaxosmithkline Biologicals Sa Method of treatment
EP3034516A1 (de) 2014-12-19 2016-06-22 Novartis AG Reinigung von Streptokokkenkapselpolysaccharid
HRP20230416T1 (hr) 2015-01-15 2023-07-07 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka
US20180071380A1 (en) 2015-03-20 2018-03-15 The Regents Of The University Of Michigan Immunogenic compositions for use in vaccination against bordetella
RU2692923C2 (ru) 2015-05-04 2019-06-28 Пфайзер Инк. Конъюгаты полисахарида стрептококка группы В и белка, способы получения конъюгатов, иммуногенные композиции, содержащие конъюгаты, и их применения
AU2016285017B2 (en) 2015-06-23 2022-03-03 Biological E Limited Multivalent pneumococcal conjugate vaccine
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
EP3269385A1 (de) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
US11191822B2 (en) 2016-06-22 2021-12-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
WO2018027126A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3031797A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3035320A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
TN2019000064A1 (en) * 2016-09-06 2020-07-15 Lg Chemical Ltd Composition comprising multivalent capsular polysaccharide-transport protein and use thereof
CA3037056A1 (en) 2016-09-30 2018-04-05 Biological E Limited Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
BR112019014833A2 (pt) 2017-01-20 2020-04-14 Pfizer composições imunogênicas para uso em vacinas pneumococais
KR102650073B1 (ko) 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
SG10202111092UA (en) 2017-01-31 2021-11-29 Pfizer Neisseria meningitidis compositions and methods thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
MX2020002555A (es) 2017-09-07 2020-09-25 Merck Sharp & Dohme Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
JP7369123B2 (ja) 2017-12-06 2023-10-25 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖類－タンパク質コンジュゲートを含む組成物およびその使用方法
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
CN112673054A (zh) 2018-07-19 2021-04-16 葛兰素史密丝克莱恩生物有限公司 用于制备干燥多糖的方法
EP3607967A1 (de) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modifizierte meningokokken fhbp polypeptide
US20220016229A1 (en) 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
CN113227125A (zh) 2018-12-12 2021-08-06 葛兰素史密丝克莱恩生物有限公司 用于o-连接的糖基化的修饰的载体蛋白
AU2019401535B2 (en) 2018-12-19 2023-12-14 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
EP3923982A1 (de) 2019-02-11 2021-12-22 Pfizer Inc. Neisseria meningitidis-zusammensetzungen und verfahren dafür
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN113966234A (zh) 2019-05-10 2022-01-21 葛兰素史克生物有限公司 缀合物的产生
EP3757217A1 (de) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Verfahren zur proteinaufreinigung
CN114728050A (zh) 2019-07-31 2022-07-08 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物及其使用方法
EP3777884A1 (de) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzung
EP4034157A1 (de) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria-meningitidis-zusammensetzungen und verfahren dafür
EP3799884A1 (de) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzungen
EP4061412A1 (de) 2019-11-22 2022-09-28 GlaxoSmithKline Biologicals S.A. Dosierung und verabreichung eines bakteriellen saccharid-glykokonjugat-impfstoffes
CN115362177A (zh) 2020-02-21 2022-11-18 辉瑞公司 糖类的纯化
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
EP3900739A1 (de) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein
EP3919076A1 (de) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetische oligosaccharidimpfstoffe gegen streptococcus pneumoniae mit mikropartikel-adjuvans-formulierungen
JP2023529925A (ja) 2020-06-12 2023-07-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ナノ粒子ワクチンを使用する細菌免疫化
EP4171624A1 (de) 2020-06-25 2023-05-03 GlaxoSmithKline Biologicals S.A. Modifizierte exotoxin-a-proteine
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
CA3192786A1 (en) 2020-08-26 2022-03-03 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
EP4213870A1 (de) 2020-09-17 2023-07-26 Janssen Pharmaceuticals, Inc. Multivalente impfstoffzusammensetzungen und verwendungen davon
JP2023546740A (ja) 2020-10-20 2023-11-07 上▲海▼瑞宙生物科技有限公司 プロテオグリカン複合体及びその用途
WO2022084852A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
WO2022097010A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
CN114965784B (zh) * 2022-06-01 2023-10-27 艾美探索者生命科学研发有限公司 多糖活化度的测定方法
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE343210B (de) * 1967-12-20 1972-03-06 Pharmacia Ab
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
DE3540076A1 (de) * 1985-11-12 1987-05-14 Boehringer Mannheim Gmbh Verfahren zur stabilisierung von creatinkinase
DE3541186A1 (de) * 1985-11-21 1987-05-27 Boehringer Mannheim Gmbh Wasserloesliche, stabilisierte peroxidasederivate, verfahren zu ihrer herstellung und verwendung zur bestimmung von wasserstoffperoxid
JPH082917B2 (ja) * 1989-11-15 1996-01-17 サンド・アクチエンゲゼルシヤフト ポリミキシン複合体
US5177059A (en) * 1989-11-15 1993-01-05 Sandoz Ltd. Polymyxin B conjugates
EP0911036A3 (de) * 1992-02-11 2001-05-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dualer Träger für immunogene Konstrukte
NZ274376A (en) * 1993-09-22 1997-11-24 Jackson H M Found Military Med Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs

Also Published As

Publication number Publication date
NL300412I1 (nl) 2009-12-01
EP0720485A1 (de) 1996-07-10
ES2210262T3 (es) 2004-07-01
DE69433341D1 (de) 2003-12-24
KR960704572A (ko) 1996-10-09
NL300411I1 (nl) 2009-12-01
CA2171942C (en) 2010-12-14
FR12C0059I1 (de) 2012-12-14
US5693326A (en) 1997-12-02
JPH09502978A (ja) 1997-03-25
JP3828145B2 (ja) 2006-10-04
EP0720485B1 (de) 2003-11-19
FR12C0059I2 (fr) 2016-10-21
US5651971A (en) 1997-07-29
AU678613B2 (en) 1997-06-05
CA2171942A1 (en) 1995-03-30
DE69433341T2 (de) 2004-04-15
ATE254475T1 (de) 2003-12-15
WO1995008348A1 (en) 1995-03-30
AU7839194A (en) 1995-04-10
NZ274376A (en) 1997-11-24
KR100376361B1 (ko) 2003-07-18

Similar Documents

Publication Publication Date Title
DE122009000058I1 (de) Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
ATE241384T1 (de) Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
WO1995008348B1 (en) Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
EP1097992A3 (de) Mpdifizierte biolumineszierende Proteine und deren Verwendung
AU563356B2 (en) Conjugate of enzyme and antibody
ATE318611T1 (de) Methoden zur produktion von elastin, auf elastin basierende biomaterialien und tropoelastin- materialien
DE69826851T2 (de) Kopplung unmodifizierter proteinen an haloacyl- oder dihaloacyl-derivatisierten polysacchariden zur herstellung von protein-polysaccharide impfstoffen
DE69325096D1 (de) Morphinderivate sowie deren konjugate und labels mit proteinen und polypeptiden
KR900009095A (ko) 합성 항원, 이의 제조방법 및 용도
FI941318A (fi) Alifaattisilla polyestereillä oksastetut tärkkelysjohdannaiset ja menetelmä niiden valmistamiseksi sekä käyttö
ATE285790T1 (de) Herstellungsverfahren von festphasekonjugateimpfstoffen
ATE187440T1 (de) Verfahren zur herstellung von substituierten 3- aminobenzonitrilen
AU7556487A (en) Immunotoxins, process for their preparation and pharmaceutical compositions in which they are present
ATE117994T1 (de) Verfahren zur herstellung von 2-chlor-5- chlormethylpyridin.
DE69332471D1 (de) Verfahren zur herstellung modifizierten proteine
AU5173996A (en) Methadone derivatives and protein and polypeptide methadone derivative conjugates and labels
SE8403929D0 (sv) Recombinant dna molecule, transformed microorganisms and process for producing penicillin v amidase
ATE309371T1 (de) Protein mit dnase-aktivität
ATE209171T1 (de) Verfahren zur herstellung von 4,4,4- trichlorbutanol
DE122009000055I1 (de) Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
DE68907490D1 (de) Verfahren zur herstellung von glukose-isomerase.
DE69228869D1 (de) Stabilisierte antikörperfragmente
DE59008084D1 (de) Verfahren zur Herstellung von Zigarettennahtleim.
ATE158173T1 (de) Verfahren zur herstellung von suppositorien durch kompression und durch dieses verfahren erhaltene suppositorien
ATE326482T1 (de) Anti-petasin-antikörper, verfahren zu ihrer herstellung und ihre verwendung